Search for: All records

Pacinian corpuscles detect transient touch and vibration in vertebrates. Corpuscles are composed of a mechanoreceptor afferent surrounded by lamellar Schwann cells (LSCs), enclosed by a multilayered outer core. The spatial arrangement of these components and their contribution to sensory tuning are unclear. We report the three-dimensional architecture of the Pacinian corpuscle and reveal the role of its cellular components in touch detection. In the prevailing model, the outer core acts as a mechanical filter that limits static and low-frequency stimuli from reaching the afferent terminal—the presumed sole site of touch detection. We show that the outer core is dispensable for the sensory tuning to transient touch and vibration; instead, these properties arise from the inner core. By acting as additional touch sensors, LSCs potentiate mechanosensitivity of the terminal, which detects touch via fast inactivating ion channels. Thus, functional tuning of the Pacinian corpuscle is enabled by an interplay between mechanosensitive LSCs and the afferent terminal in the inner core. 

Abstract Pain therapy has remained conceptually stagnant since the opioid crisis, which highlighted the dangers of treating pain with opioids. An alternative addiction-free strategy to conventional painkiller-based treatment is targeting receptors at the origin of the pain pathway, such as transient receptor potential (TRP) ion channels. Thus, a founding member of the vanilloid subfamily of TRP channels, TRPV1, represents one of the most sought-after pain therapy targets. The need for selective TRPV1 inhibitors extends beyond pain treatment, to other diseases associated with this channel, including psychiatric disorders. Here we report the cryo-electron microscopy structures of human TRPV1 in the apo state and in complex with the TRPV1-specific nanomolar-affinity analgesic antagonist SB-366791. SB-366791 binds to the vanilloid site and acts as an allosteric hTRPV1 inhibitor. SB-366791 binding site is supported by mutagenesis combined with electrophysiological recordings and can be further explored to design new drugs targeting TRPV1 in disease conditions.